Table 1.
Participants’ demographic and clinical measures.
| HD | HCs | p | |
|---|---|---|---|
| N | 18/20 | 24/49 | – |
| Sex (M/F) | 16-Sep | 39/62 | 0.135a |
| Age (y.) | 60.18 ± 9.85 (27–78) | 55.97 ± 14.45 (27–79) | 0.113b |
| Education (y.) | 13 ± 3.44 (8–17) | 11.84 ± 3.55 (5–18) | 0.104b |
| Disease duration (mo.) | 103.58 ± 163.39 (12–852) | – | – |
| UHDRS-I | 36.29 ± 15.62 (12–73) | – | – |
| UHDRS-II | 128.74 ± 51.39 (51–272) | ||
| UHDRS-III | 18.27 ± 12.68 (0–44) | ||
| UHDRS-IV | 16.65 ± 6.41 (1–25) | – | – |
| UHDRS-V | 76.22 ± 16.93 (30–100) | – | – |
| UHDRS-VI | 8.14 ± 3.71 (1–13) | – | – |
| Shoulson-Fahn | |||
| Stage 1 | 29.70% | – | – |
| Stage 2 | 35.10% | – | – |
| Stage 3 | 27% | – | – |
| Stage 4 | 8.10% | – | – |
| HTT triplets (N) | 43.53 ± 3.82 (39–59) | – | – |
| FAB | 13.5 ± 3.32 (7–18) | 17.07 ± 1.54 (11–18) | < 0.001c |
| Below-cut-off scoresd | 44.70% | 5.50% | – |
| MoCA | 20.83 ± 5.6 (9–30) | – | – |
| Below-cut-off scoree | 41.70% | – | – |
F = female; FAB=Frontal Assessment Battery; HCs = healthy controls; HD=Huntington’s disease; HTT = huntingtin; M = male; MoCA = Montreal Cognitive Assessment; UHDRS=Unified Huntington’s.
a
χ2-statistic;
b
t-statistic;
c
Mann–Whitney U-statistic;
d